How long will patients with glioblastoma survive?
- Swollen axillary lymph nodes associated with the COVID-19 vaccine last longer than initially reported
- How to relieve the fatigue symptoms of patients with Parkinson’s disease?
- Frontiers in Oncology: Mushroom extract can clear HPV infection
- Study estimates COVID-19 vaccine saved nearly 20 million lives last year
- Pfizer invests nearly US$100 million in Valneva to accelerate Lyme disease vaccine
- Cancer cells can metastasize faster while patients are sleeping
How long will patients with glioblastoma survive?
- How long can the patient live after heart stent surgery?
- More than 500 new drugs for blood diseases are in development
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
How long will patients with glioblastoma survive? How do patients with glioma survive longer?
According to the World Health Organization (WHO) pathological classification of glioma, glioblastoma in WHO grade 4 is a highly malignant tumor.
Past research data shows that the median survival time of patients with glioblastoma At 18 months, glioblastoma is still an incurable disease.
To improve the survival rate of patients with high-grade glioma, new breakthroughs in treatment are still needed.
How many years can malignant glioma live? Treatment is the key
The main methods of treatment of glioblastoma are surgery, radiotherapy and chemotherapy. There is no doubt that the scope of surgical resection of tumors is a key factor affecting the survival rate of patients.
As early as 1978, radiotherapy was discovered as a way to prolong the survival of patients with high-grade glioma;
The chemotherapeutic drug temozolomide was confirmed to be used for the treatment of recurrent high-grade glioma in 2000, and was approved for primary glioblastoma in 2005;
Bevacizumab was first approved in 2008 for the treatment of recurrent glioblastoma.
In addition, there are some new therapeutic drugs that have been clinically tested, such as cytotoxic chemotherapy drugs, anti-angiogenesis drugs, signal transduction modifiers, biological agents and immunotherapy. Each treatment method improves the survival rate of patients. Has been gradually improved.
Table 1: Potential molecular targets for glioblastoma
In recent years, a non-drug therapy has begun to show moderate survival benefits in the field of malignant tumor treatment. It is precision targeted therapy.
With the deepening of the understanding of the molecular subtypes, genomic changes, main molecular markers and signal pathways of glioblastoma in the field of neurosurgery, more accurate diagnosis and prediction of different subtypes of glioma can be made.
For example: IDH1 and IDH2 mutations are an important clue for the evolution of tumors from low-grade gliomas to high-grade gliomas; about 1%-3% of glioblastomas carry NTRK1 gene fusion; 3% of astrocytes The tumor carries NTRK2 gene fusion,
These research results will provide more information for the precise targeted therapy of high-grade gliomas.
How long will patients with glioblastoma survive?
(source:internet, reference only)
Disclaimer of medicaltrend.org
